Valproic acid hepatic fatalities: a retrospective review.
about
Off-label psychopharmacologic prescribing for children: history supports close clinical monitoringMolecular and therapeutic potential and toxicity of valproic acidEpidemiology of head injuryLearning Lessons from Adverse Drug Reactions in ChildrenDrug Induced Steatohepatitis: An Uncommon Culprit of a Common DiseaseImpact of fatty acid oxidation disorders in child neurology: from Reye syndrome to Pandora's boxAcute hemolysis with acute renal failure in a patient with valproic acid poisoning treated with charcoal hemoperfusionTreatment of valproic acid-associated hepatic failure with orthotopic liver transplantationValproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicityFatal hepatocerebral syndrome in siblings discordant for exposure to valproateTopiramate monotherapy in infantile spasmValproic acid and fatalities in children: a review of individual case safety reports in VigiBaseHepatic considerations in the use of antiepileptic drugs.Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation.Human milk biomonitoring data: interpretation and risk assessment issues.Quantitative determination of valproic acid and 14 metabolites in serum and urine by gas chromatography/mass spectrometry.Therapeutic safety monitoring: what to look for and when to look for it.Treatment of intractable childhood epilepsy with high-dose valproate.Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholismFebrile seizures: treatment and prognosis.Vigabatrin as a first-choice drug in the treatment of West syndrome.Adverse effects of antiepileptic drugs.Valproic acid toxicity: overview and management.Idiosyncratic reactions: new methods of identifying high-risk patients.Issues in the treatment of epilepsy.The importance of drug interactions in epilepsy therapy.Benign myoclonus of early infancy: an imitator of West's syndrome.Idiosyncratic drug reactions: a mechanistic evaluation of risk factorsPlasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity.A pilot study of topiramate in the treatment of infantile spasms.Therapy of infantile spasms with valproate: results of a prospective study.Identifying genomic and developmental causes of adverse drug reactions in children.Children versus adults: pharmacokinetic and adverse-effect differences.Efficacy and adverse effects of established and new antiepileptic drugs.Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States.Migraine: preventive treatment.Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009.POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disordersThe International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments.Drug metabolism and disposition in children.
P2860
Q21202071-1743F651-9A8D-4145-9043-567032834BD6Q21296867-35E573C3-2C60-4224-8365-CC2FF17AF7F5Q24676181-5B166D3C-DA4B-40C9-90C6-562F9C73E51CQ26740286-01351139-2C24-49E0-8B81-DBF37AED53B4Q26798157-30967568-2656-467F-9B7F-7D567173736AQ28085372-85AD2210-4CE7-4E16-951C-6458652A094DQ28248969-8D4B672E-B441-4566-B292-248AB31DB91EQ28320266-D40B56FB-AE39-4411-A7B4-589342DCC8A3Q28324498-5F4F0AC0-727E-43D4-9641-18F2018A1EE9Q28329559-6C1D900D-305E-44A1-9F18-C96B315B814CQ28468637-0FCC2A2D-B65F-4D89-B039-8BDC6DA717BCQ28543695-1D4196BD-70F5-4C3C-8C21-E6EA261B1232Q30461680-AC0C41EA-F53B-4259-8A89-FC7457C4C8BEQ30728586-2C02C256-6B29-4C1D-8806-A95D02699BEDQ31006357-AAF285B0-CE0F-428A-892F-A1FEA9EF9C7DQ33218447-9087A52B-8827-4BAE-99DF-496C3EFEA325Q33335206-D347DE23-A6C8-42F0-8232-FEEB44574ACEQ33374430-3F1B58CA-F160-4378-9C18-A14EAB910964Q33548809-0B70CD55-A81C-4702-AEBF-53FF5A2AB859Q33822316-16A9BC32-7E1C-4F42-8448-F89213E30E8BQ33886904-F48D5ACA-DC33-432E-8651-0A391FE82CFCQ33961524-0319D055-24C6-45C7-9F7C-A83FF5CE3926Q33963043-AA35E99A-5FED-4E94-A5CA-CDD9A6C12870Q34090578-B65D97EB-450B-4343-85F5-56DD9B6CB437Q34091794-26F70CA3-C1A0-4AD4-96AB-BB84B3493386Q34123652-9E9F671E-3903-495A-ACCA-5B30F01F632FQ34211636-2E39FCAF-AF40-48F1-8872-69C4C921CEB2Q34403403-E50276E0-B571-47F0-9C54-1EAD3F65E94BQ34408675-14501037-CA12-45D5-9BD8-FEEF72B23404Q34484322-B66BB1A5-C407-4A91-BBD7-736CA5135346Q34555374-103BFBC1-D100-4A7E-A2E0-079466A608D4Q34603032-FB906BB8-C2EE-4899-9A98-0971CE1A9A35Q34680689-28871162-9978-4FA8-9EA1-07594C1229C4Q34734496-E1FE6351-1528-4821-99D4-A15E7B92A61BQ34785900-2ADAE208-C25C-4698-9C39-DD21CFCA2CD3Q34852689-355BDC6B-767D-4A20-BF0C-D3714604C121Q34965263-CC4E7D74-2F27-4A13-8063-EE4E3BBD7F60Q34997170-6935040D-F6BE-43D7-A9F2-6AC31A21F0D4Q34998063-C95EA729-FA74-47D5-A165-1EF7790A0C26Q35152977-82A75D6E-AB66-4A96-864A-B06262764C0F
P2860
Valproic acid hepatic fatalities: a retrospective review.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Valproic acid hepatic fatalities: a retrospective review.
@en
Valproic acid hepatic fatalities: a retrospective review.
@nl
type
label
Valproic acid hepatic fatalities: a retrospective review.
@en
Valproic acid hepatic fatalities: a retrospective review.
@nl
prefLabel
Valproic acid hepatic fatalities: a retrospective review.
@en
Valproic acid hepatic fatalities: a retrospective review.
@nl
P2093
P356
P1433
P1476
Valproic acid hepatic fatalities: a retrospective review.
@en
P2093
D H Langer
F E Dreifuss
K A Moline
K B Menander
K P Sweeney
N Santilli
P304
P356
10.1212/WNL.37.3.379
P407
P577
1987-03-01T00:00:00Z